InflaRx Stock Forecast, Price & News

+0.06 (+2.25 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume244,836 shs
Average Volume469,752 shs
Market Capitalization$118.02 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

InflaRx logo

About InflaRx

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.63 out of 5 stars

Medical Sector

960th out of 1,350 stocks

Pharmaceutical Preparations Industry

473rd out of 664 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

InflaRx (NASDAQ:IFRX) Frequently Asked Questions

Is InflaRx a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" InflaRx stock.
View analyst ratings for InflaRx
or view top-rated stocks.

What stocks does MarketBeat like better than InflaRx?

Wall Street analysts have given InflaRx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InflaRx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting InflaRx?

InflaRx saw a increase in short interest in August. As of August 13th, there was short interest totaling 134,100 shares, an increase of 64.3% from the July 29th total of 81,600 shares. Based on an average daily volume of 170,800 shares, the short-interest ratio is currently 0.8 days. Approximately 0.4% of the shares of the company are short sold.
View InflaRx's Short Interest

When is InflaRx's next earnings date?

InflaRx is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for InflaRx

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) announced its quarterly earnings data on Thursday, August, 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.15.
View InflaRx's earnings history

How has InflaRx's stock been impacted by Coronavirus (COVID-19)?

InflaRx's stock was trading at $3.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IFRX shares have decreased by 15.5% and is now trading at $2.73.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IFRX?

6 brokers have issued twelve-month target prices for InflaRx's stock. Their forecasts range from $2.50 to $16.00. On average, they anticipate InflaRx's stock price to reach $8.90 in the next year. This suggests a possible upside of 226.0% from the stock's current price.
View analysts' price targets for InflaRx
or view top-rated stocks among Wall Street analysts.

Who are InflaRx's key executives?

InflaRx's management team includes the following people:
  • Niels Christoph Riedemann, Chief Executive Officer & Executive Director
  • Thomas Taapken, Chief Financial Officer
  • Renfeng Guo, Executive Director & Chief Scientific Officer
  • Maria Habel, Head-Research & Development
  • Korinna Pilz, Chief Clinical Development Officer

Who are some of InflaRx's key competitors?

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), (KDMN) and Moderna (MRNA).

When did InflaRx IPO?

(IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

Who are InflaRx's major shareholders?

InflaRx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.74%), Morgan Stanley (1.74%), Ikarian Capital LLC (1.54%), Altium Capital Management LP (0.37%), Renaissance Technologies LLC (0.31%) and Boothbay Fund Management LLC (0.20%).

Which major investors are selling InflaRx stock?

IFRX stock was sold by a variety of institutional investors in the last quarter, including Altium Capital Management LP, Ikarian Capital LLC, Algert Global LLC, and Boothbay Fund Management LLC.

Which major investors are buying InflaRx stock?

IFRX stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Marquette Asset Management LLC, Morgan Stanley, Morgan Stanley, IPG Investment Advisors LLC, Simplex Trading LLC, Renaissance Technologies LLC, and Citadel Advisors LLC.

How do I buy shares of InflaRx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $2.73.

How much money does InflaRx make?

InflaRx has a market capitalization of $118.02 million. The company earns $-38,820,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

How many employees does InflaRx have?

InflaRx employs 49 workers across the globe.

What is InflaRx's official website?

The official website for InflaRx is

Where are InflaRx's headquarters?

InflaRx is headquartered at WINZERLAER STR. 2, JENA 2M, 07745.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 493641508180 or via email at [email protected].

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.